Device Week, Jan. 31, 2019 - Livongo's Acquisition Of myStrength, FDA Evaluates Paclitaxel Devices

In this edition of Device Week, Medtech Insight's Catherine Longworth chats with Marion Webb about Livongo's acquisition of behavioral health company myStrength and with Reed Miller about the controversy surrounding the meta-analysis finding of a higher mortality risk with paclitaxel-eluting peripheral devices. Listen to the podcast via the player below: For more information on Medtech Insight and to start a free trial, click here: http://bit.ly/2w7LnlR Medtech Insight articles addressing topics discussed in this episode: SCAI, Manufacturers Defend Peripheral Paclitaxel Devices Against Doubts Livongo Buys Behavioral Health Firm in Multimillion Dollar Deal, Plans to Hire 300-500 People